NCT00363090 2013-09-20
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
Clinical Trials
6 trialsNCT00562068 2013-08-26
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00895739 2013-08-12
Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00720447 2013-08-02
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00907036 2013-08-02
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00908180 2013-08-02
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown